Phase appropriate GMP Across Cell Line Development Stages

Published on December 12, 2025
Phase appropriate GMP Across Cell Line Development Stages
Abstract

As cell therapies move from research toward clinical use, the shift from exploratory science to regulated manufacturing often introduces complexity, delays, and costly rework. If GMP is not embedded from the start, the gene edited iPSC line that is meant to support the full commercial lifecycle, may fall short of regulatory expectations later on.

Continue reading on website
Other news

Building Human-Relevant Immuno Oncology Models: A Conversation With Ncardia’s Sanne Holt

December 12, 2025
When immuno-oncology programs fall short in translation, it is often because the models used upstream do not reflect the biology that developers ultimately care about. That gap is central to the work of Sanne Holt, Associate Director Immuno Oncology at Ncardia. Her role sits at the intersection of assay design, iPSC biology, and the operational realities of drug development.

Not All Military Payers Are the Same — And That Matters More Than Ever

December 12, 2025
Zachary Schultz, Senior Director of Product Policy and Solutions at EnableComp, recently authored a thought-provoking article published in MedCity News examining a critical but often misunderstood issue in healthcare revenue cycle management: not all military payers operate the same way, and assuming they do creates real financial and operational risk for providers.In the article, Zach explains ho